Articles

Capricor Therapeutics Provides Enrollment Update on HOPE Clinical Trial in Duchenne Muscular Dystrophy

June 23, 2016

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that patient enrollment in its ongoing randomized HOPE-Duchenne clinical trial (Halt cardiomyOPathy progrEssion in Duchenne) has exceeded 50% of its 24-patient target.

Read more

Pluristem Reports Data Showing PLX -PAD Cells Effective in Treating Duchenne Muscular Dystrophy

June 22, 2016

Pluristem Therapeutics Inc . (NasdaqCM: PSTI, TASE: PSTI/ PLTR), a leading developer of placenta- based cell therapy products, today reported positive data from preclinical studies of its PLX -PAD cells in the treatment of Duchenne muscular dystrophy.

Read more

Santhera's Marketing Authorization Application for Raxone® in Duchenne Muscular Dystrophy (DMD) Validated by the European Medicines Agency

June 21, 2016

Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for Raxone® for Duchenne muscular dystrophy (DMD) in patients with respiratory function decline who are not taking concomitant glucocorticoids.

Read more

FIRST PATIENT ENROLLED IN SUMMIT'S PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN BOYS WITH DMD

June 17, 2016

Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, today announces that it has enrolled the first patient in PhaseOut DMD, a Phase 2 proof of concept clinical trial of ezutromid (formerly SMT C1100) in patients with DMD. Ezutromid dosing is expected to follow a screening period of up to 28 days.

Read more

Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA

June 14, 2016

Marathon Pharmaceuticals, LLC, a biopharmaceutical company developing treatments for rare diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug deflazacort for the treatment of patients with Duchenne muscular dystrophy (DMD), the most common and most severe form of muscular dystrophy. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.

Read more
Items 1 - 5 of 140  12345678910Next